Spots Global Cancer Trial Database for A Phase I Study of Oral BGJ398 in Asian Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I Study of Oral BGJ398 in Asian Patients
Official Title: A Phase I Study of Oral BGJ398 in Asian Patients With Advanced Solid Tumor Having Alterations of the FGF-R Pathway
Study ID: NCT01697605
Conditions
Interventions
Study Description
Brief Summary: This study will evaluate safety and tolerability to determine the Maximum tolerated dose (MTD) and/or Recommended dose (RD).
Detailed Description: This is a multi-center, open label, dose finding, phase I study of oral single agent BGJ398, administered on a continuous once and/or twice daily schedule.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Guangzhou, Guangdong, China
Novartis Investigative Site, Chengdu, Sichuan, China
Novartis Investigative Site, Guangzhou, , China
Nagoya University Hospital, Nagoya-city, Aichi, Japan
National Cancer Center Hospital East (NCEE), Kashiwa, Chiba, Japan
Novartis Investigative Site, Kobe-shi, Hyogo, Japan
Novartis Investigative Site, Sayama, Osaka, Japan
Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
